Abstract Number: 2056 • 2017 ACR/ARHP Annual Meeting
Performance and Validity of Musculoskeletal Ultrasound in the Assessment of Synovial Inflammation in Experimental Acute Gout
Background/Purpose: Musculoskeletal ultrasound (MS-US) has not been validated as a reliable technique to evaluate joint inflammation in an acute gout rabbit model. Rabbit has been…Abstract Number: 2058 • 2017 ACR/ARHP Annual Meeting
A Study on Febuxostat Prescribing Practices for Patients with Chronic Gout Previously Managed with Allopurinol at the Veterans Affairs Puget Sound
Background/Purpose: American College of Rheumatology (ACR) guidelines recommend use of either allopurinol or febuxostat as first-line approaches to urate lowering therapy in gout. Prior studies…Abstract Number: 2059 • 2017 ACR/ARHP Annual Meeting
Allopurinol Dose-Titration Patterns Relative to Serum Uric Acid Levels in Gout Patients: US Electronic Health Record Data
Background/Purpose: Gout is the most common form of inflammatory arthritis and is caused by elevated serum uric acid (sUA). Allopurinol is a first-line urate-lowering therapy…Abstract Number: 2060 • 2017 ACR/ARHP Annual Meeting
Pseudogout Among Patients Fulfilling a Billing Code Algorithm for Calcium Pyrophosphate Deposition Disease (CPPD)
Background/Purpose: Calcium pyrophosphate deposition disease (CPPD) has a spectrum of manifestations, of which pseudogout is the most acute inflammatory phenotype. Studies focusing on pseudogout are…Abstract Number: 2062 • 2017 ACR/ARHP Annual Meeting
Flow-Mediated Dilation As a Marker of Endothelial Dysfunction in Gout
Background/Purpose: Several studies have shown the relationship between gout and increased cardiovascular risk and mortality. Hyperuricemia and crystal-induced synovitis are associated with endothelial dysfunction and…Abstract Number: 2063 • 2017 ACR/ARHP Annual Meeting
Relation of Serum Urate and Gout Duration to Tophi, Urate Deposition, and Inflammation
Background/Purpose: Gout duration and serum urate (SU) levels are thought to influence development of tophi and chronic inflammatory gouty arthropathy, but the extent to which…Abstract Number: 2064 • 2017 ACR/ARHP Annual Meeting
The Nomenclature of Gout: A Content Analysis of Contemporary Medical Journals
Background/Purpose: Gout has been recognized and described since antiquity. However, the terms used to describe the disease lack standardization. The aim of this study was…Abstract Number: 2065 • 2017 ACR/ARHP Annual Meeting
Higher Urate Volume Measured By Dual Energy Computed Tomography Is Associated with Unfavourable Cardiovascular Risks in Patients with Gout
Background/Purpose: Hyperuricemia and gout are associated with increased risk of cardiovascular disease. The aim of the study was to evaluate the correlation between cardiovascular risk…Abstract Number: 2066 • 2017 ACR/ARHP Annual Meeting
Mediation Analysis to Understand Genetic Relationships between Habitual Coffee Intake and Gout
Background/Purpose: Increased coffee intake is associated with reduced serum urate concentrations and lower risk of gout. Recent genome wide association studies (GWAS) have shown that…Abstract Number: 2067 • 2017 ACR/ARHP Annual Meeting
Treatment with Pegloticase Significantly Decreases Mean Arterial Blood Pressure in Patients with Chronic Gout
Background/Purpose: There are significant correlations between serum uric acid (sUA) and blood pressure (BP) in individuals with and without gout.1 Limited data suggest that lowering…Abstract Number: 2068 • 2017 ACR/ARHP Annual Meeting
Previous Prescription of Allopurinol Reduces the Risk of Nsaids-Related Acute Kidney Injury in Patients with Gout
Background/Purpose: untreated or undertreated gout is characterized by recurrent episodes of acute inflammation of joint structures, called gout flares, and flares are commonly treated with…Abstract Number: 2069 • 2017 ACR/ARHP Annual Meeting
Gout Is More Frequent in Sickle Cell Disease Than the General Population
Background/Purpose: Despite the well known risk of hyperuricaemia in Sickle Cell Disease (SCD), it has not been determined if these patients are more prone to…Abstract Number: 2070 • 2017 ACR/ARHP Annual Meeting
Evidence-Based Development of Criteria for Complete Response in Patients with Chronic Refractory Gout
Background/Purpose: A Delphi exercise reached consensus on a definition for gout remission that included serum uric acid (sUA) <6 mg/dL, no flares, resolution of all…Abstract Number: 2073 • 2017 ACR/ARHP Annual Meeting
Predictors for Clinically Diagnosed Gout – Results from 30 Years Follow-up of the Malmö Preventive Project Cohort in Southern Sweden
Background/Purpose: Gout is the most common form of arthritis worldwide. Hyperuricemia is a crucial risk factor resulting in accumulation of uric acid (s-UA) crystals in…Abstract Number: 2074 • 2017 ACR/ARHP Annual Meeting
A Series of Double-Blind, Placebo-Controlled, Randomized, Multicenter, Phase 2 Studies to Evaluate the Efficacy, Safety, and Dose-Response Relationship of Orally Administered URC102, a Novel URAT1 Inhibitor, in Korean Patients with Gout
Background/Purpose: URC102 is a novel URAT1 inhibitor under clinical development for the treatment of hyperuricemia with gout. A series of double-blind, placebo-controlled, randomized, multicenter, phase…
Simple Search Results
Didn't find what you were looking for? Try the Advanced Search »
Didn't find what you were looking for? Try the Advanced Search »